



NEWS RELEASE

# Athersys to Announce First Quarter Financial Results on May 6

4/29/2022

Quarterly Conference Call to be Held Following Announcement of Phase 2/3 TREASURE Data in May

CLEVELAND, Ohio--(BUSINESS WIRE)-- Athersys, Inc. (Nasdaq: ATHX) today announced that it will release its first quarter 2022 financial results on Friday, May 6, 2022, at 8:00 a.m. EDT. In anticipation of the announcement of topline data from Athersys' partner, HEALIOS K.K., for its Phase 2/3 TREASURE study evaluating MultiStem® (invimestrocel, HLCM051) for the treatment of ischemic stroke in May, Athersys will host its next investor conference call after the data are released. Athersys will share the call details in its own news release reporting the data.

## About Athersys

Athersys is a biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing its MultiStem® cell therapy product, a patented, adult-derived "off-the-shelf" stem cell product, initially for disease indications in the neurological, inflammatory and immune, cardiovascular, and other critical care indications and has several ongoing clinical trials evaluating this potential regenerative medicine product. Athersys has forged strategic partnerships and a broad network of collaborations to further advance MultiStem cell therapy toward commercialization.

Investors and others should note that we may post information about the Company on our website at **www.athersys.com** and/or on our accounts on Twitter, Facebook, LinkedIn or other social media platforms. It is possible that the postings could include information deemed to be material information. Therefore, we encourage investors, the media and others interested in the Company to review the information we post on our website at **www.athersys.com** and on our social media accounts. Follow Athersys on Twitter at **www.twitter.com/athersys**. Information that we may post about the Company on our website and/or on our accounts on Twitter, Facebook, LinkedIn or other social media platforms may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. You should not place undue reliance on forward-looking statements contained on our website and/or on our accounts on Twitter, Facebook, LinkedIn or other social media platforms, and we undertake no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise.

Ivor Macleod  
Chief Financial Officer  
Tel: (216) 431-9900  
**ir@athersys.com**

Karen Hunady  
Director of Corporate Communications and Investor Relations  
Tel: (216) 431-9900  
**khunady@athersys.com**

David Schull  
Russo Partners, LLC  
Tel: (212) 845-4271 or (858) 717-2310  
**David.schull@russopartnersllc.com**

Peter Vozzo  
ICR Westwicke  
Tel: (443) 213-0505  
**peter.vozzo@westwicke.com**

Source: Athersys, Inc.